Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Tough Market And Policy Challenges Loom, J&J Names New India Leadership For Pharma Business

This article was originally published in PharmAsia News

Executive Summary

With former MSD hand Sanjiv Navangul as its new India CEO, experts believe J&J will make deeper inroads in the country. The new leader will be expected to make his way through regulatory bottlenecks at home while convincing global leadership to launch new drugs quickly for the Indian market.

You may also be interested in...



J&J Shines Spotlight On U.S. OTC Sales Growth

Domestic OTC sales grow nearly 20% to $644 million as J&J remains on track to return 75% of recalled McNeil products to market. Consumer business head Sandra Peterson says the firm began breaking out OTC sales figures to single out how the business is doing.

J&J Gains FDA OK For First-In-Class Type 2 Diabetes Drug Invokana

J&J is the first pharma company to bring an SGLT2 inhibitor to market, but its window of exclusivity in that class may be narrow, given that FDA is slated to assess two other SGLT2s later this year.

Merck Vows To Be In Top Five In India By 2015; Push Will Come From 13 New Launches In The Next Two Years

MUMBAI - Buoyed by strong performance of its key brands Januvia (sitagliptin) and Gardasil launched last year in India, U.S. drug giant Merck is going full throttle in its ambition to figure in the top five companies in India by 2015

Topics

Related Companies

UsernamePublicRestriction

Register

SC085335

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel